Utilizing Natural Language Processing to Examine the Risk of Arthralgia Between Vedolizumab and Tumor Necrosis Factor Inhibitors in Inflammatory Bowel Disease

被引：0
|
作者：
Lin, Tzu-Chieh [1 ]
Cai, Tianrun [1 ]
Kane-Wanger, Gwendolyn [1 ]
Cagan, Andrew [2 ]
Murphy, Shawn N. [3 ]
Ananthakrishnan, Ashwin [3 ]
Liao, Katherine P. [1 ]
机构：
[1] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[2] Partners HealthCare, Charlestown, MA USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2017年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
53
引用
收藏
页码：35 / 36
页数：2
相关论文
共 50 条
  • [1] The Association Between Arthralgia and Vedolizumab Using Natural Language Processing
    Cai, Tianrun
    Lin, Tzu-Chieh
    Bond, Allison
    Huang, Jie
    Kane-Wanger, Gwendolyn
    Cagan, Andrew
    Murphy, Shawn N.
    Ananthakrishnan, Ashwin N.
    Liao, Katherine P.
    INFLAMMATORY BOWEL DISEASES, 2018, 24 (10) : 2242 - 2246
  • [2] Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease
    Peyrin-Biroulet, Laurent
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (26): : 2561 - 2561
  • [3] Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease
    Nielsen, Ole Haagen
    Ainsworth, Mark Andrew
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (08): : 754 - 762
  • [4] Risk of Serious Infections With Vedolizumab Versus Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease
    Kirchgesner, Julien
    Desai, Rishi J.
    Beaugerie, Laurent
    Schneeweiss, Sebastian
    Kim, Seoyoung C.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (02) : 314 - +
  • [5] Tumor Necrosis Factor Inhibitors in Inflammatory Bowel Disease and Risk of Immune Mediated Inflammatory Diseases
    Ward, Daniel
    Andersen, Nynne Nyboe
    Gortz, Sanne
    Iversen, Aske Thorn
    Allin, Kristine Hojgaard
    Beaugerie, Laurent
    Kirchgesner, Julien
    Jess, Tine
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (01) : 135 - 143
  • [6] Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor-α Antagonists in Patients with Inflammatory Bowel Diseases
    Singh, Siddharth
    Heien, Herbert C.
    Sangaralingham, Lindsey
    Shah, Nilay D.
    Sandborn, William J.
    DIGESTIVE DISEASES AND SCIENCES, 2022, 67 (06) : 2510 - 2516
  • [7] Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor-α Antagonists in Patients with Inflammatory Bowel Diseases
    Siddharth Singh
    Herbert C. Heien
    Lindsey Sangaralingham
    Nilay D. Shah
    William J. Sandborn
    Digestive Diseases and Sciences, 2022, 67 : 2510 - 2516
  • [8] Vedolizumab Trough Levels in Children With Anti-Tumor Necrosis Factor Refractory Inflammatory Bowel Disease
    Aardoom, Martine A.
    Jongsma, Maria M. E.
    de Vries, Annick
    Wolthoorn, Jasja
    de Ridder, Lissy
    Escher, Johanna C.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2020, 71 (04): : 501 - 507
  • [9] Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases
    Singh, Siddharth
    Heien, Herbert C.
    Herrin, Jeph
    Dulai, Parambir S.
    Sangaralingham, Lindsey
    Shah, Nilay D.
    Sandborn, William J.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (02) : E74 - E88
  • [10] A Comparison of Weight Gain Profiles of Tumor Necrosis Factor (TNF)-Alpha Inhibitors, Ustekinumab, and Vedolizumab in the Treatment of Patients With Inflammatory Bowel Disease (IBD)
    Mohan, Navina
    Stewart, Oliver
    Leben, Arielle
    Axelrad, Jordan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S832 - S833
12345